New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Allogene Therapeutics, Inc. (ALLO) vs Vanda Pharmaceuticals Inc. (VNDA)
- Allogene Therapeutics, Inc. ALLO 0.63 −5.97%
- Vanda Pharmaceuticals Inc. VNDA 3.45 −5.99%
Allogene Therapeutics, Inc. and Vanda Pharmaceuticals Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Vanda Pharmaceuticals Inc. are of similar size ($235.2M and $231.1M). Vanda Pharmaceuticals Inc. grew revenue faster over the last twelve months: 8.11% against −30.4%. Vanda Pharmaceuticals Inc. has the higher net margin (−119.9% vs −335,973.6%) and the lower return on invested capital (−180.2% vs −119.4%). Across the 16 metrics below, Allogene Therapeutics, Inc. leads on 12 and Vanda Pharmaceuticals Inc. on 4.
Valuation
Profitability
| Metric | ALLO | VNDA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 93.59% | 70.18% |
| Operating margin | (342,700.00%) | (77.59%) | 0.00% |
| Net margin | (335,973.56%) | (119.87%) | 0.00% |
| Free cash flow margin | (261,473.56%) | — | 0.00% |
| Return on equity | (49.29%) | (82.55%) | (51.58%) |
| Return on assets | (36.69%) | (55.89%) | (45.91%) |
| Return on invested capital | (119.37%) | (180.19%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack